Neuroprotection: Challenges and opportunities

Archives of Neurology

Volumn 64, Issue 6, 2007, Pages 794-800

  Faden, Alan I ^a   Stoica, Bogdan ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXANABINOL; ERYTHROPOIETIN; GLUTAMATE RECEPTOR ANTAGONIST; MAGNESIUM SULFATE; METHYLPREDNISOLONE; MONOAMINE OXIDASE INHIBITOR; NALOXONE;

CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE MODEL; GENOMICS; HEAD INJURY; HUMAN; NEUROPROTECTION; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SPINAL CORD INJURY; STROKE;

ANIMALS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; CRANIOCEREBRAL TRAUMA; DRUG EVALUATION, PRECLINICAL; GENOMICS; HUMANS; NEUROPROTECTIVE AGENTS; PROTEOMICS; RESEARCH; SPINAL CORD INJURIES;

EID: 34250305937     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.6.794     Document Type: Review

References (42)

1. Yakovlev AG, Faden AI. Mechanisms of neural cell death: implications for development of neuroprotective treatment strategies. NeuroRx. 2004;1:5-16.
2. Grotta J. Neuroprotection is unlikely to be effective in humans using current trial design. Stroke. 2002;33:306-307.
3. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx. 2004;1:36-45.
4. Faden AI. Neuroprotection and traumatic brain injury: theoretical option or realistic proposition. Curr Opin Neurol. 2002;15:707-712.
5. Fox GB, LeVasseur RA, Faden AI. Behavioral responses of C57BL/6, FVB/N, and 129/SvEMS mouse strains to traumatic brain injury: implications for gene targeting approaches to neurotrauma. J Neurotrauma. 1999;16:377-389.
6. Roof RL, Hall ED. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotrauma. 2000;17:367-388.
7. Slewa-Younan S, Green AM, Baguley IJ, Gurka JA, Marosszeky JE. Sex differences in injury severity and outcome measures after traumatic brain injury. Arch Phys Med Rehabil. 2004;85:376-379.
8. Statler KD, Alexander H, Vagni V, et al. Comparison of seven anesthetic agents on outcome after experimental traumatic brain injury in adult, male rats. J Neurotrauma. 2006;23:97-108.
9. Wahlgren NG, Ahmed N. Neuroprotection in cerebral ischaemia: facts and fancies - the need for new approaches. Cerebrovasc Dis. 2004;17(supp 1):153-166.
10. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-477.
11. Tolias CM, Bullock MR. Critical appraisal of neuroprotection trials in head injury: what have we learned? NeuroRx. 2004;1:71-79.
12. Bracken MB, Holford TR. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2. J Neurosurg. 1993;79:500-507.
13. Faden AI, Jacobs TP, Smith MT, Zivin JA. Naloxone in experimental spinal cord ischemia: dose-response studies. Eur J Pharmacol. 1984;103:115-120.
14. Edwards P, Arango M, Balica L, et al. Final results of MRC CRASH, a randomized placebo-controlled trial of intravenous corticosteroid in adults with head injury: outcome at 6 months. Lancet. 2005;365:1957-1959.
15. Watts DD, Hanfling D, Waller MA, Gilmore C, Fakhry SM, Trask AL. An evaluation of the use of guidelines in prehospital management of brain injury. Prehosp Emerg Care. 2004;8:254-261.
16. Chesnut RM. Management of brain and spine injuries. Crit Care Clin. 2004;20:25-55.
17. Faden AI, Knoblach SM, Movsesyan VA, Lea PM IV, Cernak I. Novel neuroprotective tripeptides and dipeptides. Ann N Y Acad Sci. 2005;1053:472-481.
18. Pitts LH, Ross A, Chase GA, Faden AI. Treatment with thyrotropin- releasing hormone (TRH) in patients with traumatic spinal cord injuries. J Neurotrauma. 1995;12:235-243.
19. Cutler SM, Pettus EH, Hoffman SW, Stein DG. Tapered progesterone withdrawal enhances behavioral and molecular recovery after traumatic brain injury. Exp Neurol. 2005;195:423-429.
20. Murphy SJ, Littleton-Kearney MT, Hurn PD. Progesterone administration during reperfusion, but not preischemia alone, reduces injury in ovariectomized rats. J Cereb Blood Flow Metab. 2002;22:1181-1188.
21. Faden AI, Movsesyan VA, Knoblach SM, Ahmed F, Cernak I. Neuroprotective effects of novel small peptides in vitro and after brain injury. Neuropharmacology. 2005;49:410-424.
22. Callaway JK, Beart PM, Jarrott B, Giardina SF. Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis. Br J Pharmacol. 2001;132:1691-1698.
23. Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol. 2006;18:132-138.
24. Villa P, van Beek J, Larsen AK, et al. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab. 2007;27:552-563.
25. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295-309.
26. Cernak I. Recent advances in neuroprotection for treating traumatic brain injury. Expert Opin Investig Drugs. 2006;15:1371-1381.
27. Maas AI, Murray G, Henney H III, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 2006;5:38-45.
28. McKee JA, Brewer RP, Macy GE, Borel CO, Reynolds JD, Warner DS. Magnesium neuroprotection is limited in humans with acute brain injury. Neurocrit Care. 2005;2:342-351.
29. Mattson MP, Duan W, Wan R, Guo Z. Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations. NeuroRx. 2004;1:111-116.
30. Sharma S, Kaur G. Neuroprotective potential of dietary restriction against kainite-induced excitotoxicity in adult male Wistar rats. Brain Res Bull. 2005;67:482-491.
31. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116-1127.
32. Schmeer C, Kretz A, Isenmann S. Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins. Restor Neurol Neurosci. 2006;24:79-95.
33. Uchida S, Fujiki M, Nagai Y, Abe T, Kobayashi H. Geranylgeranylacetone, a non-invasive heat shock protein inducer, induces protein kinase C and leads to neuroprotection against cerebral infarction in rats. Neurosci Lett. 2006;396:220-224.
34. Lu A, Ran R, Parmentier-Batteur S, Nee A, Sharp FR. Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia. J Neurochem. 2002;81:355-364.
35. Wu D. Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx. 2005;2:120-128.
36. Di Giovanni S, Movsesyan V, Ahmed F, et al. Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc Natl Acad Sci U S A. 2005;102:8333-8338.
37. Byrnes KR, Garay J, Di Giovanni S, et al. Expression of two temporally distinct microglia-related gene clusters after spinal cord injury. Glia. 2006;53:420-433.
38. Liu MC, Akle V, Zheng W, et al. Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis. Biochem J. 2006;394:715-725.
39. Ashby D. Bayesian statistics in medicine: a 25 year review. Stat Med. 2006;25:3589-3631.
40. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752-2758.
41. Fong JJ, Rhoney DH. NXY-059: review of neuroprotective potential for acute stroke. Ann Pharmacother. 2006;40:461-471.
42. Koziol JA, Feng AC. On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke. Stroke. 2006;37:2644-2647.